Finance

Lists
AVBP:NASDAQ
Arrivent Biopharma Inc
$28.90
+1.90%
(+0.54) 1D
Sep 18, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AVBP...
Open
$29.00
High
$29.64
Low
$28.62
Mkt. cap
1.42B
Avg. vol.
440.09K
Volume
0.00
52-wk high
$35.83
52-wk low
$17.00
EPS
-$3.67
Shares outstanding
49.31M
No. of employees
77
Open
$29.00
High
$29.64
Low
$28.62
Mkt. cap
1.42B
Avg. vol.
440.09K
Volume
0.00
52-wk high
$35.83
52-wk low
$17.00
EPS
-$3.67
Shares outstanding
49.31M
No. of employees
77
News stories
From web sources and news partners
About Arrivent Biopharma Inc
CEO-
Employees77
Founded2021
HeadquartersNewtown Square, Pennsylvania, United States
SectorBiotechnology
Websitearrivent.com
Analyst ratings
Based on 8 analysts giving stock ratings to AVBP in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for AVBP in the last 3 months.
Highest
Current $28.90
$50.00 (+73.01%)
Average
$44.57 (+54.22%)
Lowest
$40.00 (+38.41%)
Analyst
Recommendation
Action
Price target
Projected
Date
Supawat Thongthip
Truist Financial
Buy
Maintained
-
-
09/15/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$45.00
+55.7%
09/15/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$40.00
+38.4%
09/14/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$43.00
+48.8%
09/14/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$47.00
+62.6%
08/17/2026
Asthika Goonewardene
Truist Financial
Buy
Maintained
$45.00
+55.7%
08/13/2026
Jeff Jones
Oppenheimer
Buy
Maintained
$50.00
+73%
08/13/2026
Jeet Mukherjee
BTIG
Buy
Maintained
$42.00
+45.3%
08/12/2026
Boris Peaker
JonesTrading
Buy
Maintained
$45.00
+55.7%
08/12/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
$45.00
+55.7%
05/29/2026
Soumit Roy
JonesTrading
Buy
Maintained
$45.00
+55.7%
04/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
32.17M
32.18M
37.62M
42.34M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.15M
6.65M
8.49M
10.35M
Operating expense
38.32M
38.82M
46.11M
52.69M
Total operating expenses
38.32M
38.82M
46.11M
52.69M
Operating income
-38.32M
-38.82M
-46.11M
-52.69M
Other non operating income
-
-
-
-
EBT including unusual items
-34.75M
-35.96M
-43.32M
-49.89M
EBT excluding unusual items
-34.98M
-35.54M
-43.32M
-49.89M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-34.75M
-35.96M
-43.32M
-49.89M
Net profit margin
-
-
-
-
Earnings per share
-0.83
-0.78
-0.96
-1.05
Interest and investment income
3.34M
3.28M
2.79M
2.80M
Interest expense
-
-
-
-
Net interest expenses
3.34M
3.28M
2.79M
2.80M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps